Description

TELMAHEAL 40 MG (1X15)

Indications

TELMAHEAL 40 MG is primarily indicated for the treatment of hypertension (high blood pressure) in adults. It can be used alone or in combination with other antihypertensive agents. Effective management of hypertension is crucial as it helps in reducing the risk of cardiovascular events such as stroke, heart attack, and kidney problems. Additionally, TELMAHEAL may be indicated for patients with heart failure or those at risk of developing cardiovascular diseases.

Mechanism of Action

The active ingredient in TELMAHEAL is Telmisartan, which belongs to a class of medications known as angiotensin II receptor antagonists (ARBs). Telmisartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By inhibiting this hormone, Telmisartan promotes vasodilation (widening of blood vessels), which leads to a decrease in blood pressure. This mechanism not only helps in managing hypertension but also provides protective effects on the heart and kidneys.

Pharmacological Properties

Telmisartan exhibits a high affinity for the angiotensin II receptor subtype AT1, which is primarily responsible for the effects of angiotensin II. The drug has a long half-life, allowing for once-daily dosing, which enhances patient compliance. Telmisartan is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 1 hour after oral administration. The drug is extensively metabolized in the liver, and its metabolites are primarily excreted in the urine and feces. Telmisartan does not have significant effects on heart rate and is not associated with the development of tachycardia.

Contraindications

TELMAHEAL is contraindicated in patients who are hypersensitive to Telmisartan or any of the excipients in the formulation. It should not be used in patients with severe renal impairment or those who are pregnant or breastfeeding. Additionally, the medication is contraindicated in patients with biliary obstructive disorders. Caution is advised when prescribing TELMAHEAL to patients with a history of angioedema associated with previous treatment with an ACE inhibitor or ARB.

Side Effects

Common side effects of TELMAHEAL include dizziness, fatigue, and headache. These side effects are generally mild and transient. However, some patients may experience more serious adverse effects such as hypotension (low blood pressure), renal impairment, and hyperkalemia (elevated potassium levels). In rare cases, patients may develop allergic reactions, including angioedema. It is essential for patients to report any unusual symptoms or side effects to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of TELMAHEAL for adults is typically 40 mg once daily. Depending on the patient’s response and blood pressure levels, the dose may be increased to a maximum of 80 mg once daily. It is advisable to take TELMAHEAL at the same time each day to maintain consistent blood levels. The tablet should be swallowed whole with water and can be taken with or without food. Patients should follow their healthcare provider’s instructions regarding dosage adjustments and duration of therapy.

Interactions

TELMAHEAL may interact with other medications, which could either enhance or reduce its antihypertensive effects. Co-administration with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of Telmisartan. It is essential for patients to inform their healthcare provider about all medications, including over-the-counter drugs and supplements, to avoid potential drug interactions.

Precautions

Before initiating treatment with TELMAHEAL, healthcare providers should assess the patient’s renal function and electrolyte levels, particularly potassium. Special caution is warranted in patients with a history of renal artery stenosis, heart failure, or those undergoing diuretic therapy. Patients should be monitored for signs of hypotension, especially after the first dose or when the dose is increased. It is also important to advise patients to maintain adequate hydration to prevent dehydration and renal complications.

Clinical Studies

Several clinical studies have demonstrated the efficacy of Telmisartan in reducing blood pressure and improving cardiovascular outcomes. A randomized controlled trial showed that patients treated with Telmisartan experienced significant reductions in systolic and diastolic blood pressure compared to placebo. Furthermore, long-term studies indicated that Telmisartan not only effectively managed hypertension but also provided renal protection in patients with diabetic nephropathy. These findings support the use of TELMAHEAL as a first-line treatment option for hypertension.

Conclusion

TELMAHEAL 40 MG is an effective antihypertensive medication that offers a well-tolerated option for managing high blood pressure. Its unique mechanism of action, along with its favorable pharmacokinetic profile, makes it suitable for long-term use in various patient populations. While generally safe, it is essential for patients to adhere to prescribed dosages and report any adverse effects to their healthcare provider. Regular monitoring of blood pressure and renal function is recommended to ensure optimal therapeutic outcomes.